LONDON (Reuters) - U.S. drug company Endo Pharmaceuticals' gel designed to prevent infection with the AIDS virus was ineffective in trials in Africa, Britain's Medical Research Council (MRC) said on Monday.
The large international trial of vaginal microbicide Pro 2000 in more than 9,000 women in four African countries found no evidence that it reduces the risk of HIV infection.
Already a subscriber? Log in.
Win a prize this Mother's Day by subscribing to our annual plan now! T&C applies.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!
